ClearID® Lab Tests

Focused on rapid advancement in the molecular biology field, Cynvenio’s genomic tests accurately target known mutations in cancer-related genes to revolutionize personalized treatment decision making and clinical trial selection.

Among its breakthroughs is an expanding line of ClearID® tests engineered for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and proprietary LiquidBiopsy® technology that makes real-time molecular characterization from whole blood a reality. 

ClearID Cancer Panels

The analysis of circulating biomarkers in blood has become a valuable practice for the real-time monitoring of individual patients. Using ClearID genomic testing, physicians can assess patients’ individual mutations and match them with targeted cancer therapies and clinical trials. ClearID is low risk and easily repeatable, requiring only a standard blood sample, and is the only commercial test to interrogate both ctcDNA (circulating tumor cell DNA) as well as cfDNA (cell-free DNA).  

ClearID Total Insight

ClearID Total Insight is a new liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.  Generally performed at regular intervals throughout the year, ClearID Total Insight consists of four ClearID DNA sequencing tests, four NK-Score™ immune system assessment tests, and a BRCA 1 & 2 test provided in partnership with Color Genomics.


NK Score Immune System Monitoring

NK cell function has been shown to be affected in a number of conditions and diseases. In the past few decades, many studies have demonstrated that NK cell activity is much lower in individuals with different types of cancers. Although low NK cell activity does not indicate a disease or an illness, it can indicate the health of the immune system and alert physicians when more aggressive surveillance is required, or trigger additional testing.  


PD-L1 Expression Assay

A test to provide real-time PD-L1 status to advanced cancer patients before, during and after immunotherapy.